FINWIRES · TerminalLIVE
FINWIRES

Zhejiang Xianju Pharmaceutical Gets FDA's Abbreviated New Drug Application for Progesterone Vaginal Tablets

By

The U.S. Food and Drug Administration accepted Zhejiang Xianju Pharmaceutical's (SHE:002332) abbreviated new drug application for progesterone vaginal tablets, according to a Wednesday filing with the Shenzhen bourse.

The tablets help support embryo implantation and early pregnancy by supporting luteal function, according to the filing.

What else is happening in Asia?